NAD+ · Research brief

NAD+ and Chronic Fatigue: Complete Research Guide 2026

Real Peptides Research TeamEditorial

Updated April 24, 202610 min read

60 WORDS

Short answer

Key takeaways

NAD+ is described in the literature as declining with age, and that decline is mechanistically tied to reduced mitochondrial ATP synthesis efficiency; the specific magnitude is not reproduced here because no PubMed-linked citation accompanies it on this page.
Oral NAD+ itself has near-zero bioavailability due to gut degradation and membrane impermeability. Only precursors such as NMN and NR are described as reaching systemic circulation and converting to NAD+ intracellularly.
Human trials of NMN and NR report increases in circulating NAD+, but those trials were run in populations other than chronic fatigue cohorts — extending them to CFS or ME is inference, not evidence.
NAD+ depletion is described as accelerated by CD38 activity (upregulated with age and inflammation) and by PARP overactivation during chronic oxidative stress.
IV NAD+ produces a transient rise in circulating NAD+ that returns toward baseline within roughly a day, consistent with extracellular degradation by CD38 rather than sustained intracellular uptake.
The mitochondrial mechanism explains why rest alone would not be expected to restore NAD+ if the salvage pathway is impaired — the ATP production pathway itself is operating at reduced capacity.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, acting as the electron carrier for glycolysis, the citric acid cycle and the mitochondrial electron transport chain — the pathway that converts nutrients and oxygen into ATP. Research on NAD+ biology describes an age-associated decline in tissue NAD+ and, at the mechanistic level, links reduced NAD+ availability to lower mitochondrial ATP synthesis efficiency. Whether raising NAD+ changes fatigue in people diagnosed with chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME) is a separate and far less settled question: human trials run specifically in those populations are thin. Most of what follows comes from NAD+ biochemistry, preclinical models and precursor studies conducted in other populations — mechanistic and indirect evidence, clearly labelled as such, not compound-specific proof for chronic fatigue.

One honesty note shapes this entire guide. The percentages, time points and journal names that circulate in NAD+ marketing copy are not reproduced here, because this page carries no PubMed-linked citations to pair them with. Rather than attribute findings loosely to a named study or review, we report the mechanism, the direction of effect the literature describes, and an explicit label wherever the reasoning is inferential rather than measured.

Our team has worked with researchers investigating NAD+ biology for over a decade. The shift from framing chronic fatigue as a purely psychosomatic condition to investigating it as a metabolic problem with measurable biomarkers — NAD+/NADH ratios, mitochondrial respiration rates, sirtuin activity — has reshaped what the field chooses to measure.

What is NAD+, and how is its depletion linked to chronic fatigue in the research?

NAD+ is required for electron transport chain function, the process mitochondria use to convert glucose and oxygen into ATP — the molecule that powers muscle contraction, neurotransmitter synthesis and immune response. Biochemically, when NAD+ availability falls below the level the dehydrogenase enzymes need, flux through glycolysis and the citric acid cycle slows, fewer electrons reach the respiratory complexes, and ATP output per molecule of glucose oxidised falls. That is the mechanistic chain researchers use to connect NAD+ depletion to persistent fatigue: cells operating at reduced energy-generating capacity regardless of rest or caloric intake. It is a mechanism description, not a demonstrated clinical outcome.

The mistake most people make is treating fatigue as a single condition. Chronic fatigue isn't one diagnosis. It's a symptom cluster with multiple potential drivers, and NAD+ depletion is only one candidate among them — though it is the one that offers a mechanistic explanation for why rest alone would not restore energy, since the ATP production pathway itself is described as operating at reduced capacity. This guide covers NAD+ biosynthesis and salvage pathways, how precursor routes such as NMN and NR differ mechanistically from direct NAD+ infusion, what the trial literature has and has not established, and where the evidence remains preclinical.

How NAD+ Depletion Is Linked to Chronic Fatigue in the Research

NAD+ functions as an electron carrier in glycolysis and the citric acid cycle. Without sufficient NAD+ availability, these metabolic pathways slow, reducing substrate flow into the electron transport chain. The mechanistic result: fewer protons pumped across the mitochondrial membrane, lower ATP synthase activity, and reduced cellular energy output. Comparisons of NAD+/NADH ratios and mitochondrial respiration between chronic fatigue syndrome cohorts and healthy controls have been reported in the literature, but because this page carries no PubMed citation for those comparisons, the specific magnitudes are not reproduced here — and the direction of effect should be read as mechanistic reasoning rather than a settled, compound-specific finding.

The depletion is described as occurring through multiple pathways. CD38, an enzyme upregulated with age and chronic inflammation, degrades NAD+ into nicotinamide and ADP-ribose at accelerating rates with age. PARP enzymes consume NAD+ during DNA repair. Chronic oxidative stress from poor diet, environmental toxins or persistent viral infection is described as driving PARP overactivation, which would create an NAD+ deficit independent of age. Sirtuins — the longevity-associated enzymes that regulate mitochondrial biogenesis and cellular stress resistance — require NAD+ as a cofactor, so falling NAD+ is expected to reduce sirtuin activity and compound mitochondrial dysfunction. This is well-characterised enzymology; none of it, on its own, demonstrates a fatigue outcome.

Here is what working alongside metabolic researchers makes obvious: NAD+ restoration would not be expected to change function quickly, because mitochondrial biogenesis — the creation of new, functional mitochondria — takes weeks to months, requiring protein synthesis, membrane remodelling and organellar integration. Assay-measurable changes in blood NAD+ and changes in functional or subjective measures therefore run on different timescales. The literature available on this page does not specify the exact intervals, so no figures are given.

NAD+ Precursors vs Direct Infusion: Bioavailability and Mechanism Comparison

NAD+ cannot cross cell membranes intact. Its molecular weight and charge prevent passive diffusion. This is why direct oral NAD+ shows near-zero bioavailability: the molecule is degraded in the gut before reaching systemic circulation. The workaround studied in the literature is NAD+ precursors — NMN, NR (nicotinamide riboside) and niacin — which cells convert into NAD+ via the salvage and Preiss-Handler pathways.

NMN bypasses one enzymatic step compared with NR. It is described as entering cells via the Slc12a8 transporter and being converted to NAD+ by NMNAT enzymes without requiring nicotinamide riboside kinase. Human trials of oral NMN have reported increases in circulating NAD+ in generally healthy adults; because no PubMed-linked citation accompanies those results on this page, the reported percentages and time points are not reproduced. NR requires conversion to NMN before NAD+ synthesis, adding one rate-limiting step, and is described in the literature as showing better stability in acidic gastric conditions. Neither comparison was made in a chronic fatigue population in any study cited here.

Direct NAD+ infusion bypasses gut degradation entirely, but the mechanism argues against a large intracellular effect: infused NAD+ remains largely extracellular or is degraded by CD38 on endothelial cells before uptake, and the intact molecule does not diffuse across membranes. Reports of acute subjective effects after infusion exist, alongside circulating NAD+ measurements returning toward baseline within about a day. That pattern is consistent with rapid extracellular degradation — again, mechanistic interpretation, not a controlled trial result available on this page.

Research-grade peptides such as Thymalin and Cerebrolysin are discussed in relation to immune regulation and neurotrophin signalling. No direct study linking either compound to NAD+ biosynthesis in chronic fatigue is cited on this page; the connection is mechanistic reasoning drawn from general peptide science rather than compound-specific evidence. Both are supplied for research use only and are not for human consumption.

NAD+ Chronic Fatigue Complete Guide 2026: What the Trial Literature Reports

Intervention	Route and mechanism	Direction of effect described in the literature	Evidence status
NMN (oral)	Enters cells via the Slc12a8 transporter; converted by NMNAT enzymes; bypasses the nicotinamide riboside kinase step	Increases in circulating NAD+ over repeated weeks of intake	Human data exist outside chronic fatigue populations; no PubMed-linked citation on this page, so percentages and time points are not reproduced
NR (oral)	Converted to NMN by nicotinamide riboside kinase before NAD+ synthesis; described as more stable in acidic gastric conditions	Increases in circulating NAD+ with marked between-individual variability; gastrointestinal discomfort reported at higher intakes	Human data exist outside chronic fatigue populations; not citable here, so no figures are given
NAD+ IV infusion	Bypasses gut degradation, but intact NAD+ does not cross membranes; extracellular CD38 degrades it rapidly	Transient rise in circulating NAD+ returning toward baseline within roughly a day	Mechanistic interpretation; no controlled chronic fatigue trial cited on this page
Niacin (flush form)	Feeds the Preiss-Handler and salvage pathways; histamine-mediated flushing widely described	Slower accumulation of NAD+ relative to NMN and NR	Long-standing pharmacology; tolerability limited by flushing; chronic fatigue endpoints not established here
MK 677 + NMN combination	Growth hormone secretagogue signalling proposed to interact with mitochondrial biogenesis pathways that use NAD+	Not established in either direction	Preclinical and mechanistic only; no published human trial identified — this row is a hypothesis, not a finding

The mechanistic summary, stated as mechanism rather than as a citation-backed roll-up: NAD+ cannot enter cells intact, precursors can, and the salvage pathway is saturable, so beyond a certain intake the excess is excreted rather than converted. Infusion raises circulating NAD+ acutely without a mechanism for sustained intracellular elevation. Any claim about how far any of this moves fatigue scores in patients would require trial citations this page does not carry, and is therefore not made.

What If: NAD+ Chronic Fatigue Scenarios

What If NAD+ Rises on Assay but Fatigue Measures Don't Move?

This is the expected pattern under the mechanism as described. Raising NAD+ acts upstream of mitochondrial biogenesis rather than on immediate ATP output, and new mitochondria require protein synthesis and integration over weeks. Elevated NAD+ would first drive sirtuin activation, mitochondrial membrane remodelling and increased oxidative phosphorylation capacity before any functional measure could change. Where functional measures remain flat over longer observation, the research literature treats that as evidence that NAD+ depletion was not the rate-limiting factor in that individual — cortisol dysregulation, thyroid dysfunction and iron deficiency anaemia are all described as independent drivers of the same symptom cluster.

What If Chronic Fatigue Has a Driver Other Than NAD+?

NAD+ depletion is one biological pathway among many associated with chronic fatigue. The fatigue literature describes functional iron deficiency, subclinical hypothyroidism, adrenal insufficiency, low vitamin B12, undiagnosed sleep apnea, chronic Epstein-Barr virus reactivation and post-viral mitochondrial damage following COVID-19 as producing overlapping presentations. Specific diagnostic thresholds vary by laboratory and guideline and are not specified here. The relevant research point: NAD+ restoration only addresses the NAD+ pathway, and conditions driven by other mechanisms remain unaddressed by it.

What If NAD+ Precursors Are Studied Alongside Other Mitochondrial Compounds?

CoQ10 (ubiquinone) acts downstream of NAD+ within the electron transport chain, so combining it with a precursor targets two different steps of the same ATP synthesis sequence — a rationale, not a demonstrated combined effect. Alpha-lipoic acid participates in redox cycling that regenerates oxidised cofactors and has been proposed as a way to extend functional NAD+ turnover. Compounds such as Dihexa, which is investigated for BDNF signalling and neuroplasticity, are discussed in relation to cognitive fatigue specifically. All of this is early research territory, and no combination trial in chronic fatigue populations is cited on this page.

The Unflinching Truth About NAD+ and Chronic Fatigue

Here is the honest position: NAD+ is not established as a treatment for chronic fatigue. It is a metabolic pathway that the research describes as relevant only where NAD+ depletion is actually rate-limiting for mitochondrial function. Marketing around NAD+ therapy implies universal energy restoration regardless of underlying cause, and that is not what the published record supports. Precursors such as NMN and NR are reported to raise systemic NAD+ in human trials run in other populations; whether that translates into measurable change in a chronic fatigue cohort has not been demonstrated in any study cited here, and the human data in that specific population remain thin.

Most people investigated for unexplained chronic fatigue present with multiple overlapping contributors — NAD+ depletion, thyroid dysfunction, chronic inflammation, disrupted sleep architecture, insulin resistance — and a single-pathway intervention leaves the others untouched. The value of a 2026 guide to NAD+ and chronic fatigue is not a protocol; it is a clear map of which parts of this picture are measured enzymology, which are preclinical, and which are still hypothesis. All compounds referenced on this page are research-grade materials supplied for research use only and are not for human consumption.

References

Peer-reviewed sources on NAD+ indexed in PubMed, listed for research context. Real Peptides supplies NAD+ for laboratory research use only.

NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing research reviews, 2026. PMID 41655607. doi:10.1016/j.arr.2026.103057
NAD(+) restores proteostasis through splicing-dependent autophagy. Autophagy, 2026. PMID 41313318. doi:10.1080/15548627.2025.2596679
Endothelial NAD(+) depletion drives vascular senescence and neuroinflammation via mtDNA-cGAS/STING-CD38 signaling in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. PMID 42033099. doi:10.1002/alz.71423
NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations. JCI insight, 2026. PMID 41574612. doi:10.1172/jci.insight.181812
NAD(+) depletion drives age-related monocyte hyperinflammation after stroke and is reversed by nicotinamide riboside. Journal of neuroinflammation, 2025. PMID 41299539. doi:10.1186/s12974-025-03638-6
Lactate dehydrogenase A-coupled NAD(+) regeneration is critical for acute myeloid leukemia cell survival. Cancer & metabolism, 2025. PMID 40390151. doi:10.1186/s40170-025-00392-4
FOXO1-NMNAT3 axis dysregulation promotes doxorubicin cardiotoxicity: NAD(+) replenishment as a redox-targeted antioxidant therapy. Redox report : communications in free radical research, 2025. PMID 41021886. doi:10.1080/13510002.2025.2565033
NAD+ prevents chronic kidney disease by activating renal tubular metabolism. JCI insight, 2025. PMID 40059824. doi:10.1172/jci.insight.181443

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The research is mechanistic rather than conclusive. NAD+ is required as the electron carrier for glycolysis, the citric acid cycle and the electron transport chain, and low NAD+ availability is described as reducing mitochondrial ATP output — which gives a plausible explanation for fatigue that rest does not resolve. Human trials specifically in chronic fatigue syndrome or ME populations are thin, and the precursor trials most often quoted were run in other populations. This page carries no PubMed-linked citations, so no trial percentages are reproduced here; treat the NAD+–fatigue connection as mechanistic reasoning and preclinical work rather than demonstrated compound-specific evidence.

Assay-measurable change in circulating NAD+ and change in functional or subjective measures run on different timescales, because mitochondrial biogenesis — the creation of new, functional mitochondria — requires protein synthesis and organellar integration over weeks. The literature available on this page does not specify exact intervals, and no figures are given without a citation to pair them with. The separation of the two timescales is itself a mechanistic prediction, not a measured outcome reported here.

No study cited on this page establishes that. CFS and ME are described in the literature as multifactorial, involving immune dysregulation, mitochondrial dysfunction and neuroinflammation, and the NAD+ pathway addresses only one of those mechanisms. Clinical trials in CFS and ME populations specifically are limited, which is why the evidence base here is characterised as thin and largely preclinical or mechanistic.

NMN (nicotinamide mononucleotide) is described as entering cells via the Slc12a8 transporter and being converted to NAD+ by NMNAT enzymes, bypassing the nicotinamide riboside kinase step that NR (nicotinamide riboside) requires. NR, in turn, is described as more stable in acidic gastric conditions. Both routes feed the same salvage pathway. Head-to-head comparisons in chronic fatigue populations are not cited on this page, so no claim of superiority is made in either direction.

Yes, and the difference is structural. Intact NAD+ does not cross cell membranes because of its molecular weight and charge, and extracellular enzymes such as CD38 degrade it rapidly, so infusion raises circulating NAD+ transiently with measurements returning toward baseline within roughly a day. Oral precursors instead enter the salvage pathway and are converted intracellularly. This is mechanism, not a controlled comparison — no trial comparing the two routes in chronic fatigue is cited here.

The fatigue literature describes thyroid dysfunction, functional iron deficiency, low vitamin B12, undiagnosed sleep apnea, chronic Epstein-Barr virus reactivation, post-viral mitochondrial damage and cortisol dysregulation as producing chronic fatigue through mechanisms independent of NAD+ status. Specific diagnostic thresholds vary by laboratory and guideline and are not specified here. The research-relevant point is that NAD+ restoration acts on one pathway only.

Direct NAD+ quantification in blood or tissue is largely confined to research settings rather than routine testing. Metabolomic panels reporting NAD+/NADH and lactate-to-pyruvate ratios are used as indirect indicators of mitochondrial redox state. There is no validated diagnostic that identifies NAD+ depletion as the cause of an individual's fatigue, and this page describes what such assays measure rather than offering any assessment pathway.

Not for chronic fatigue. Published trials of NMN and NR examined a range of intakes in other populations, and because no PubMed-linked citation accompanies those figures on this page, they are not reproduced. The salvage pathway is described as saturable, meaning intake beyond a certain point is excreted rather than converted to NAD+. These materials are supplied for research use only and are not for human consumption.

Combination work is early. CoQ10 acts downstream of NAD+ within the electron transport chain and alpha-lipoic acid participates in redox cycling that regenerates oxidised cofactors, which gives a mechanistic rationale for pairing them with a precursor — but no combination trial in chronic fatigue populations is cited on this page. Exercise is described independently as activating PGC-1α through AMPK signalling, another mitochondrial biogenesis input. All of this is labelled mechanistic reasoning, not demonstrated synergy.

Short-term human trials of NMN and NR report general tolerability, with gastrointestinal discomfort noted at higher intakes, and niacin in its flush form is widely described as causing histamine-mediated flushing that limits tolerability. Long-term safety data beyond roughly a year are limited, and the theoretical question of whether elevated NAD+ interacts with tumour cell metabolism is raised in the literature without resolution. No PubMed-linked citation accompanies these reports on this page, and these compounds are research-grade materials for laboratory research only.

Sleep and rest restore glycogen and clear metabolic waste, but neither increases NAD+ biosynthesis if the salvage pathway is constrained by age-related CD38 upregulation or PARP overconsumption during chronic oxidative stress. Under that mechanism, ATP synthesis efficiency stays reduced regardless of rest, because the coenzyme required for electron transport remains functionally depleted. That is the mechanistic explanation researchers use for fatigue persisting despite adequate sleep; it is reasoning from enzymology rather than a measured clinical finding cited here.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA